Issue 2/2016
Content (26 Articles)
Identifying novel therapeutic agents using xenograft models of pediatric cancer
Raushan T. Kurmasheva, Peter J. Houghton
The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside
A. Zaniboni, V. Formica
Anti-VEGF and anti-EGFR agents open up new horizons changing the landscape for their associations
Gerard Milano
Rho GTPases: RAC1 polymorphisms affected platinum-based chemotherapy toxicity in lung cancer patients
Ting Zou, Jiye Yin, Wei Zheng, Ling Xiao, Liming Tan, Juan Chen, Ying Wang, Xiangping Li, Chenyue Qian, Jiajia Cui, Wei Zhang, Honghao Zhou, Zhaoqian Liu
A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors
Junning Cao, Jian Zhang, Wei Peng, Zhiyu Chen, Songhua Fan, Weiguo Su, Ke Li, Jin Li
Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors
David C. Smith, John Powderly, James J. Lee, Dale R. Shepard, Johan Wallin, Archana Chaudhary, Grace Yi Chao, Wee Teck Ng, Malcolm I. Mitchell, Gerrit Grau, Raffael Kurek, Patricia LoRusso
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer
Yutaka Fujiwara, Kenji Tamura, Shunsuke Kondo, Yuko Tanabe, Satoru Iwasa, Akihiko Shimomura, Shigehisa Kitano, Ken Ogasawara, P. Kellie Turner, Joji Mori, Hiroya Asou, Edward Michael Chan, Noboru Yamamoto
A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer
Seiji Yoshitomi, Naruto Taira, Hiroyoshi Doihara, Taeko Mizoo, Tomohiro Nogami, Takayuki Iwamoto, Takayuki Motoki, Tadahiko Shien, Yutaka Ogasawara, Junji Matsuoka, Hisashi Tsuji, Toshiharu Mitsuhashi
Cystatin C as a predictor factor in patients with renal cell carcinoma treated by everolimus
Lubomir Bodnar, Rafał Stec, Małgorzata Dzierżanowska, Agnieszka Synowiec, Szczepan Cierniak, Grzegorz Kade, Cezary Szczylik
Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma
Ayana Tomono, Kaori Ito, Takahiro Hayashi, Maiko Ando, Yosuke Ando, Masahiro Tsuge, Akinao Okamoto, Yoko Inaguma, Masataka Okamoto, Nobuhiko Emi, Shigeki Yamada
Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma
Elliot Kahen, Diana Yu, Douglas J. Harrison, Justine Clark, Pooja Hingorani, Christopher L. Cubitt, Damon R. Reed
Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features
Jwa Hoon Kim, Inkeun Park, Jae Lyun Lee
High TUG1 expression is associated with chemotherapy resistance and poor prognosis in esophageal squamous cell carcinoma
Lin Jiang, Wenchao Wang, Guoli Li, Canlin Sun, Zhenqin Ren, Haihui Sheng, Hengjun Gao, Chaofu Wang, Hong Yu
Population pharmacokinetics of bevacizumab in cancer patients with external validation
Kelong Han, Thomas Peyret, Mathilde Marchand, Angelica Quartino, Nathalie H. Gosselin, Sandhya Girish, David E. Allison, Jin Jin
Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma
Vikram Gota, Ashwin Karanam, Sanhita Rath, Akanksha Yadav, Prashant Tembhare, P. Subramanian, Manju Sengar, Reena Nair, Hari Menon
TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer
D. Ferraro, D. Goldstein, R. L. O’Connell, J. R. Zalcberg, K. M. Sjoquist, N. C. Tebbutt, P. Grimison, S. McLachlan, L. L. Lipton, P. Vasey, V. J. Gebski, C. Aiken, M. Cronk, S. Ng, C. S. Karapetis, J. Shannon, J. Shannon, D. Goldstein, N. Tebbutt, S. Ng, M. Cronk, C. Karapetis, K. Sjoquist, C. Aiken, V. Do, I. Marschner, M. Friedlander, H. Gurney, J. Simes, W. Hague, R. O’Connell, V. Gebski, C. Aiken, M. Gorzeman, R. Pike, K Miranda, P. Waring, D. Ferraro, D. Lau, S. Fox, N. Tebbutt, Y. Liu, P. Vasey, T. Wood, M. Cronk, C. Cocks, K. Simmons, J. Shannon, J. McCourt, M. Jefford, A. Hobinchet, P. Grimison, B. Mirco, J. Sagong, S. Ng, S. Dudukovic, M. Aghmesheh, S. Parker, E. Segelov, L. Ratnayake, S. McLachlan, N. Ranieri, S. Varma, J. Page, E. Heyer, E. Abdi, C. Chorlton, L. Lipton, L. Wilkinson
Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG)
A. Matikas, Ν. Kentepozidis, A. Ardavanis, M. Vaslamatzis, A. Polyzos, Ch. Emmanouilides, P. Katsaounis, F. Koinis, S. Xynogalos, A. Christopoulou, N. Ziras, Th. Tegos, E. Prinarakis, D. Hatzidaki, V. Georgoulias, A. Kotsakis
Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations
Kosuke Mizoguchi, Yoichi Nakamura, Kazumi Sano, Shuntaro Sato, Yoji Ikegami, Kohei Motoshima, Shinnosuke Takemoto, Daiki Ogawara, Hiroaki Senju, Nanae Sugasaki, Takaya Ikeda, Hiroyuki Yamaguchi, Katsumi Nakatomi, Minoru Fukuda, Koichi Izumikawa, Hiroshi Mukae
A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer
Yusuke Okuma, Yukio Hosomi, Satoshi Takahashi, Yoshiro Nakahara, Kageaki Watanabe, Makoto Nagamata, Yusuke Takagi, Shinichiro Mikura
Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancer
Tsuyoshi Hata, Toshihiro Kudo, Daisuke Sakai, Hidekazu Takahashi, Naotsugu Haraguchi, Junichi Nishimura, Taishi Hata, Tsunekazu Mizushima, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori, Taroh Satoh
Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer
Toshi Takaoka, Tetsuo Kimura, Rai Shimoyama, Shunji Kawamoto, Kazuki Sakamoto, Fuminori Goda, Hiroshi Miyamoto, Yuji Negoro, Akihito Tsuji, Koji Yoshizaki, Takahiro Goji, Shinji Kitamura, Hiromi Yano, Koichi Okamoto, Masako Kimura, Toshiya Okahisa, Naoki Muguruma, Yoshiro Niitsu, Tetsuji Takayama
A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors
Klaus Mross, Heike Richly, Annette Frost, Dirk Scharr, Bahar Nokay, Ralph Graeser, Chooi Lee, James Hilbert, Rainer-George Goeldner, Oliver Fietz, Max E. Scheulen
New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma
Cécile Teuma, Marie Perier-Muzet, Solenne Pelletier, Mathilde Nouvier, Mona Amini-Adl, Frédérique Dijoud, Gérard Duru, Luc Thomas, Denis Fouque, Maurice Laville, Stéphane Dalle
Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib
Lisa H. Lam, Edmund V. Capparelli, Razelle Kurzrock
Lack of pharmacokinetic drug–drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors
Laura Q. M. Chow, David C. Smith, Antoinette R. Tan, Crystal S. Denlinger, Ding Wang, Dale R. Shepard, Archana Chaudhary, Yong Lin, Ling Gao